-
- SAKUMA Hiroko
- Department of Pediatrics, Fukushima Medical College
-
- SATOH Tomoko
- Department of Pediatrics, Fukushima Medical College
-
- MATSUMOTO Emiko
- Department of Pediatrics, Fukushima Medical College
-
- KANNO Hiroyuki
- Department of Pediatrics, Fukushima Medical College
-
- WATANABE Masakatsu
- Department of Pediatrics, Fukushima Medical College
-
- KIKUTA Atsushi
- Department of Pediatrics, Fukushima Medical College
-
- SUZUKI Hitoshi
- Department of Pediatrics, Fukushima Medical College
Bibliographic Information
- Other Title
-
- 薬剤性出血性膀胱炎に対する血液凝固第XIII因子製剤の有効性についての検討
Abstract
The therapeutic effects of Factor XIII (F XIII) concentrate against drug-induced hemorrhagic cystitis (HC) was investigated. HC ocurred in 4 children with malignant disease during anti-cancer chemotherapy. Two (CML and T-ALL) of 4 patients developed HC after the administration of high dose cyclophosphamide as conditioning for allo bone marrow transplantation or peripheral blood stem cell autografts, and the otehr 2 patients (rhabdomyosarcoma, Wilm's tumor) developed HC after the administration of ifosfamide for relapse. When F XIII concentrate at a dose of 20 to 230 U/kg was administrated immediately after the onset of HC, the symptomes, i.e., bladder irritability and macrohematuria disappeared within a few days. The F XIII serum levels of those patients were low (27∼57%), and the levels increased (63∼230%) after administration of F XIII concentrate. The two patients with relapsed solid tumor showed no symptoms of HC during subsequent ifosfamide treatment when F XIII concentrate was administrated to maintain a normal F XIII range. These results suggest that the administration of F XIII concentrate may be useful for the prophylaxis and treatment of drug-induced HC in patients with a low F XIII level.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 35 (3), 279-285, 1994
The Japanese Society of Hematology